176693-88-2

Upstream product

• 105166-35-6 2-(3-methoxyphenyl)propanoic acid ethyl ester 
• 3146-60-9 2-(3-methoxyphenyl)propanoic acid 

Downstream Products

• 385390-32-9 N-(2,2-dimethyl-4H-[1,3]dioxin-5-yl)-2-(3-methoxy-phenyl)-N-methyl-propionamide 
• 176693-81-5 3-{4-Isopropyl-2-[1-(3-methoxy-phenyl)-ethyl]-5-oxo-2,5-dihydro-oxazol-2-yl}-propionitrile 
• 176693-87-1 4-[(E)-Methoxyimino]-5-(3-methoxy-phenyl)-hexanoic acid 
• 176693-85-9 5-(3-Methoxy-phenyl)-4-oxo-hexanoic acid 
• 176693-83-7 5-(3-Methoxy-phenyl)-4-oxo-hexanenitrile 
• 791780-36-4 O-methyl-aphanorphine 
• 952710-32-6 N-(2,2-dimethoxy-ethyl)-2-(3-methoxy-phenyl)-propionamide 
• 176693-78-0 2-[2-(3-Methoxy-phenyl)-propionylamino]-3-methyl-butyric acid 

Relevant academic research and scientific papers

Total synthesis of (±)-lennoxamine and (±)-aphanorphine by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins

equation presented Intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins constitute the key steps in the total syntheses of lennoxamine and aphanorphine. The aldehyde moiety of one cyclization product was transformed to a double

BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL

The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndr

Benzosuberane-5,8-diones

Two 5-aryl-4-oxopentanoic acids were made from appropriate valine oxazolones, protected as the 4-methoxyimino derivatives and cyclised to tetrahydrobenzo[7]annulene-5,8-diones (1).